|Bid||151.11 x 800|
|Ask||151.37 x 800|
|Day's Range||141.57 - 152.32|
|52 Week Range||38.88 - 152.32|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||126.50|
Pfizer CEO sees need for a third vaccine dose as Moderna updates its timeline on third booster shot. Pause on the Johnson & Johnson vaccine remains. Yahoo Finance’s Anjalee Khemlani breaks down the details.
Blood clot concerns lack context, experts say, putting pressure on federal agencies to unpause J&J vaccinations.
Achieving herd immunity through mass vaccination involves a delicate — sometimes tricky — dance with side effects, public opinion and virus variants. The rollout of coronavirus vaccines has not been without challenges, but the government’s goal to not rely on just one vaccine has limited the scope of a setback involving any one product. The Food and Drug Administration and the Centers for Disease Control and Prevention recommended a pause in the use of the Johnson & Johnson vaccine this week as they examine six severe cases of blood clots.